Elanco Animal Health: The Commercialization of Zenrelia & Its Expansion in Farm Animal Sector Are Upping The Game!

Elanco Animal Health reported its financial performance for the first quarter of 2025, revealing several key aspects of its operational and strategic positioning. The company outperformed its expectations in revenue, adjusted EBITDA, and adjusted EPS, marking a continuation of its growth trajectory. A significant achievement was a 4% organic constant currency revenue growth, underpinned equally by price and volume increases. Revenue from new products was particularly strong, prompting an upward revision of the expected full-year contribution from these innovations.